CD19 CAR-T 细胞治疗滤泡性淋巴瘤后重度银屑病长期缓解

Long-term Remission of Severe Psoriasis Following CD19 CAR-T Cell Therapy for Follicular Lymphoma.

基于重复时间-事件模型的 Epcoritamab 剂量递增方案选择与优化以降低细胞因子释放综合征风险

Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation.

基于已发表 Kaplan-Meier 曲线重建的个体患者数据对复发/难治性滤泡性淋巴瘤当代二线及后线治疗进行持久性基准评估

Durability Benchmarking of Contemporary Second-Line and Later Therapies for Relapsed or Refractory Follicular Lymphoma Using Reconstructed Individual

超越化疗免疫治疗：转化型滤泡性淋巴瘤中新兴的细胞治疗与靶向治疗：范围综述

Beyond Chemoimmunotherapy: Emerging Cellular and Targeted Therapies in Transformed Follicular Lymphoma: A Scoping Review.

B 细胞非霍奇金淋巴瘤中的 CD20 × CD3 双特异性抗体：当前证据、治疗整合与未来方向

CD20 × CD3 Bispecific Antibodies in B-Cell Non-Hodgkin Lymphomas: Current Evidence, Therapeutic Integration, and Future Directions.

滤泡性淋巴瘤合并 POD24 患者的治疗与生存结局：系统综述与荟萃分析

Treatment and survival outcomes for patients with follicular lymphoma and POD24: a systematic review and meta-analysis.

relmacabtagene autoleucel（CD19 CAR-T）治疗中国成人复发/难治性套细胞淋巴瘤的 2 期研究

Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults.

在靶点选择指导下，inotuzumab ozogamicin 成功挽救一例抗 CD19 和抗 CD22 CAR-T 细胞治疗后的难治性滤泡性淋巴瘤患者：病例报告与文献综述

Guided by target selection, inotuzumab ozogamicin successfully salvaged a patient with refractory follicular lymphoma after anti-CD19 and anti-CD22 CA

滤泡性淋巴瘤患者诊断、治疗与随访指南——西班牙淋巴瘤组 (GELTAMO) 2025

Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025.

FL 是一种异质性疾病，需要个体化的管理策略。

系统综述与荟萃分析：CAR-T 对比双特异性抗体作为滤泡性淋巴瘤三线及后线治疗

Systematic review and meta-analysis: CAR-T vs bispecific antibody as third or later-line therapy for follicular lymphoma.